This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

The company says they will create hundreds of new jobs between 2028 and 2032, and the average pay will be more than $91,000 a year.

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

Amgen (AMGN) ended the recent trading session at $277.88, demonstrating a +1.62% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.53 ...

Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office ...

Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor ...